**Suppl. Table 1 Patient disease characteristics at baseline**

| **Patient** | **Age (years)** | **Duration of ocular inflammatory disease up to index date (years)** | **Aetiology (activity of underlying disease)**  | **Duration of systemic inflammation (years)** | **Anatomic Classification of Uveitis**  | **Uveitis phenotype** | **Co-morbidities** | **Smoking status** | **Visual acuity at baseline** | **Vitreous haze score** | **Indication for starting biologic therapy** | **Unilateral or bilateral disease** | **Duration of biologic therapy (years)** | **Immunosuppressive therapy at baseline** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | 32 | 3 | Behcet’s disease (active) | 4 | Posterior uveitis | Retinal vasculitis (macula-involving)  | None | Current smoker | RE 0, LE 0 | RE 0, LE 0 | Intolerance to other immunosuppression | Missing | 10 | Prednisolone 20mgTacrolimus 2mgMycophenolate 1.5g |
| 2 | 38 | 5 | Anklylosing spondylosis (active) | 9 | Anterior uveitis | Anterior inflammation | Epiretinal membrane | Ex-smoker | RE 0.3, LE 0.5 | RE 0, LE 0 | Intolerance to other immunosuppression | Unilateral (RE) | 8 | Methotrexate 10mg |
| 3 | 45 | 10 | Idiopathic  | Not applicable | Posterior uveitis | Retinal vasculitis (occlusive, macula-involving)  | Epiretinal membrane | Ex-smoker | RE 0.5, LE 0 | RE 0, LE 0 | Failure to control inflammationEarly aggressive sight loss | Bilateral | 7 | Prednisolone 10mg Tacrolimus 4mgMycophenolate 2g |
| 4 | 26 | 3 | Behcet’s disease (active) | 4 | Posterior uveitis | Retinal vasculitis (occlusive, peripheral)  | None | Never smoked | RE -0.2, LE -0.2 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 9 | Prednisolone 25mgTacrolimus 6mgMycophenolate 2g |
| 5 | 38 | 1 | Behcet’s disease (active) | 0 | Panuveitis | Retinal vasculitis (macula-involving)  | None | Current smoker | RE 0.5, LE 0 | RE 0, LE 0 | Intolerance to other immunosuppression | Bilateral | 11 | Prednisolone 15mgTacrolimus 2mg  |
| 6 | 43 | 5 | Behcet’s disease (active) | 1 | Posterior uveitis | Retinal vasculitis (occlusive, peripheral)  | Epiretinal membrane | Ex-smoker | RE -0.1, LE 0.5 | RE 0, LE 0 | Failure to control inflammation | Missing | 3 | Prednisolone 20mgTacrolimus 4mgMycophenolate 2g |
| 7 | 52 | 7 | Psoriatic arthropathy (active) | 16 | Intermediate uveitis | None | GlaucomaCataract | Never smoked | RE 0.7, LE 0.2 | RE 3, LE 0 | Failure to control inflammation | Bilateral | 9 | Methotrexate 20mg |
| 8 | 47 | 2 | Behcet’s disease (active) | 1 | Posterior uveitis | Retinal vasculitis (occlusive, peripheral)  | Glaucoma | Never smoked | RE 1.3, LE 0.2 | RE 0, LE 0 | Intolerance to other immunosuppression | Bilateral | 10 | Prednisolone 20mgTacrolimus 2mg |
| 9 | 62 | 1 | Undifferentiated arthritis (active) | 2 | Scleritis | None | None | Ex-smoker | RE 1.5, LE 0.8 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 10 | Methotrexate 20mg |
| 10 | 41 | 4 | Idiopathic  | Not applicable | Posterior uveitis | Retinal vasculitis (occlusive, peripheral) Vitritis | Cystoid macular oedema | Current smoker | RE 0, LE 0.3 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 9 | Prednisolone 15mgCyclosporine 300mg |
| 11 | 25 | 3 | Behcet’s disease (active) | 3 | Posterior uveitis | Retinal vasculitis (peripheral) | Epiretinal membrane | Missing | RE 0, LE 0 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 8 | Tacrolimus 6mgMycophenolate 3g |
| 12 | 24 | 6 | Idiopathic  | Not applicable | Panuveitis | Retinal vasculitis (peripheral) | Cataract | Missing | RE 0.2, LE 0.2 | RE 1, LE 2 | Failure to control inflammationIntolerance to other immunosuppression | Missing | 10 | Prednisolone 40mgMethotrexate 20mg |
| 13 | 47 | 10 | Idiopathic  | Not applicable | Posterior uveitis | None | Cystoid macular oedemaEpiretinal membrane | Ex-smoker | RE 0.8, LE 1 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 7 | Prednisolone 15mgTacrolimus 5mg  |
| 14 | 51 | 10 | Idiopathic  | Not applicable | Posterior uveitis | Retinal vasculitis (occlusive, macula-involving)  | Choroidal neovascularisation | Missing | RE 0.8, LE 0.8 | RE 0, LE 0 | Failure to control inflammation | Missing | 1 | Prednisolone 8mgTacrolimus 6mgMycophenolate 2g |
| 15 | 40 | 9 | Behcet’s disease (active) | 10 | Panuveitis | Retinal vasculitis (macula-involving)  | Epiretinal membraneCystoid macular oedema  | Current smoker | RE 0.8, LE 1.5 | RE 1, LE 1 | Failure to control inflammationIntolerance to other immunosuppression | Bilateral | 12 | Prednisolone 30mgCyclosporine 150mgMycophenolate 3g |
| 16 | 29 | 2 | Idiopathic | Not applicable | Posterior uveitis | Missing | Missing | Missing | Missing | Missing | Missing | Missing | 5 | Prednisolone 8mgTacrolimus 4mgMycophenolate 2g |
| 17 | 33 | 3 | Idiopathic  | Not applicable | Posterior uveitis | Retinal vasculitis (occlusive, macula-involving)  | None | Current smoker | RE 0.2, LE 0 | RE 0, LE 0 | Early aggressive sight loss | Bilateral | 3  | Prednisolone 60mgTacrolimus 3mgMycophenolate 2g |
| 18 | 18 | 10 | JIA (active) | 15 | Anterior uveitis | None | None | Never smoked | RE 0, LE -0.1 | RE 0, LE 0 | Missing | Bilateral | 7 | Prednisolone 10mgMycophenolate 2gMethotrexate 17.5mg |
| 19 | 53 | 1 | Behcet’s disease (active) | 7 | Posterior uveitis | Retinal vasculitis (peripheral) | CataractEpiretinal membrane | Missing | RE 0.2, LE 0.3 | RE 0, LE 0 | Intolerance to other immunosuppression | Bilateral | 7 | Prednisolone 10mgTacrolimus 4mgMycophenolate 2g |
| 20 | 31 | 18 | JIA (active) | 20 | Intermediate uveitis | Anterior inflammation | GlaucomaCataract | Never smoked | RE 0.5, LE 3 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 7 | Prednisolone 30mgMycophenolate 3gMethotrexate 25mg |
| 21 | 22 | 13 | Idiopathic  | Not applicable | Intermediate uveitis | Retinal vasculitis (macula-involving)  | Ocular hypertensionCataractCystoid macular oedema | Never smoked | RE 0.2, LE 0.2 | RE 0, LE 0 | Failure to control inflammationIntolerance to other immunosuppression | Bilateral | 9 | Cyclosporine 150mgMycophenolate 1.5g |
| 22 | 34 | 1 | Behcet’s disease (active) | 1 | Panuveitis | Anterior inflammationVitritisRetinal vasculitis (peripheral) | Epiretinal membrane | Missing | RE 0.1, LE 0.1 | RE 0, LE 0 | Early aggressive sight loss | Unilateral (LE) | 7 | Prednisolone 5mgTacrolimus 4mgMycophenolate 2g |
| 23 | 52 | 10 | Idiopathic  | Missing | Intermediate uveitis | Vitritis | Cataract Epiretinal membraneCystoid macular oedema | Never smoked | RE 0.6, LE 0.2 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 7 | Prednisolone 20mgTacrolimus 4mgMycophenolate 3g |
| 24 | 58 | 1 | ANCA negative vasculitis - active | 1 | Scleritis | None | None | Missing | RE 0, LE 0 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 8 | Prednisolone 25mgAzathioprine 100mg |
| 25 | 20 | 7 | Idiopathic  | Not applicable | Intermediate uveitis | Vitritis | Glaucoma | Never smoked | RE 0, LE 0.6 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 9 | Prednisolone 7.5mgTacrolimus 4mgMycophenolate 2g |
| 26 | 44 | 2 | Behcet’s disease (active) | 0 | Panuveitis | Retinal vasculitis (occlusive, macula-involving) VitritisAnterior inflammation | Cystoid macular oedema | Never smoked | RE 2, LE 3 | RE 0, LE 4 | Intolerance to other immunosuppressionEarly aggressive sight loss | Alternating disease | 6 | Prednisolone 30mgTacrolimus 2mgMycophenolate 1g |
| 27 | 28 | 2 | Idiopathic - mouth ulceration | 2 | Intermediate uveitis | Vitritis | Cystoid macular oedema | Ex-smoker | RE 0.1, LE 0.1 | RE 1, LE 1 | Failure to control inflammation | Bilateral | 5 | Tacrolimus 4mgMycophenolate 3g |
| 28 | 38 | 1 | Idiopathic  | Not applicable | Posterior uveitis | Retinal vasculitis (occlusive, peripheral)  | Cystoid macular oedema | Current smoker | RE 0.48, LE 0.3 | RE 0, LE 0 | Failure to control inflammationEarly aggressive sight loss | Bilateral | 6 | Tacrolimus 2mgMycophenolate 1g |
| 29 | 40 | 3 | Behcet’s disease (active) | 3 | Panuveitis | Retinal vasculitis (peripheral) | None | Current smoker | RE 2.5, LE 2.5 | RE 0, LE 0 | Failure to control inflammationHigh dose steroid requirement | Bilateral | 9 | Prednisolone 50mgCyclosporine 300mg |
| 30 | 41 | 0 | Psoriatic arthropathy (active) | 6 | Scleritis | None | None | Never smoked | RE 0.2, LE 0.2 | RE 0, LE 0 | Early aggressive sight loss | Unilateral (RE) | 6 | Prednisolone 20mgMethotrexate 20mg |
| 31 | 41 | 0 | Idiopathic  | Not applicable | Posterior uveitis | Retinal vasculitis (occlusive, peripheral)  | None | Ex-smoker | RE 1, LE -0.1 | RE 0.5, LE 0.5 | Early aggressive sight loss | Bilateral | 6 | Prednisolone 5mgMycophenolate 2gMethotrexate 12.5mg |
| 32 | 32 | 8 | Idiopathic  | Not applicable | Intermediate uveitis | Anterior inflammationVitritis | GlaucomaCataractEpiretinal membraneCystoid macular oedema | Missing | Missing | RE 0, LE 0 | Failure to control inflammation | Bilateral | 1 | Prednisolone 10mgTacrolimus 2mgMycophenolate 3g |
| 33 | 47 | 1 | Behcet’s disease (active) | 1 | Anterior uveitis | Anterior inflammation | None | Never smoked | RE 0.15, LE 0.15 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 8 | Prednisolone 10mgMethotrexate 20mg |
| 34 | 20 | 8 | Juvenile sarcoidosis (active) | 8 | Panuveitis | Anterior inflammationVitritis | CataractHypotonyOptic disc swellingOptic atrophy | Never smoked | RE 0.3, LE 1 | RE 0, LE 0 | Failure to control inflammation | Bilateral | 6 | Prednisolone 20mgMethotrexate 20mg |
| 35 | 32 | 0 | Behcet’s disease (active) | 3 | Posterior uveitis | Retinal vasculitis (macula-involving)  | None | Current smoker | RE 0, LE 1.25 | RE 0, LE 0 | Intolerance to other immunosuppressionEarly aggressive sight loss | Unilateral (LE) | 3 | Prednisolone 20mgTacrolimus 2mg |
| 36 | 23 | 6 | Idiopathic - no systemic disease | Not applicable | Panuveitis | Vitritis | GlaucomaCataractEpiretinal membrane | Missing | RE 0.6, LE 0.3 | RE 1, LE 1 | Failure to control inflammation | Bilateral | 5 | Tacrolimus 2mgMycophenolate 2g |
| 37 | 47 | 1 | Idiopathic – CNS involvement | 1 | Panuveitis | Retinal vasculitis (peripheral)Choroidal inflammation | None | Never smoked | RE 0.9, LE 0.7 | RE 0.5, LE 0.5 | Failure to control inflammation | Bilateral | 4 | Tacrolimus 3mgMycophenolate 2g |
| 38 | 54 | 0 | Idiopathic  | Not applicable | Scleritis | None | Cataract | Never smoked | RE 0.1, LE 0.8 | RE 0, LE 0 | Intolerance to other immunosuppression | Unilateral | 5 | Prednisolone 10mgMethotrexate 15mg |
| 39 | 45 | 4 | Behcet’s disease (active) | Missing | Panuveitis | Retinal vasculitis (peripheral) | Epiretinal membraneCystoid macular oedema | Never smoked | RE -0.1, LE -0.1 | RE 0, LE 0 | Failure to control inflammationHigh dose steroid requirement | Bilateral | 5 | Prednisolone 7.5mgTacrolimus 4mgMycophenolate 3g |
| 40 | 51 | 5 | Sarcoidosis (active) | 5 | Panuveitis | Anterior inflammationVitritis | Ocular hypertensionCataractEpiretinal membraneCystoid macular oedema | Missing | RE 0.7, LE 0.2 | RE 1, LE 0.5 | Failure to control inflammation | Bilateral | 4 | Prednisolone 15mgTacrolimus 3mgMycophenolate 3g |
| 41 | 57 | 3 | Behcet’s disease - (active) | 0 | Panuveitis | Retinal vasculitis (occlusive, peripheral) Vitritis | CataractCystoid macular oedema | Never smoked | RE 2, LE 0.9 | RE 1, LE 0 | Failure to control inflammation | Bilateral | 3 | Tacrolimus 4mgMycophenolate 3g |
| 42 | 52 | Missing | Idiopathic | Not applicable | Missing | Missing | Epiretinal membraneCystoid macular oedema | Missing | RE 0.6, LE 0.6 | RE 0, LE 0 | Intolerance to other immunosuppression | Missing | 3 | Prednisolone 7.5mg |
| 43 | 18 | 8 | Idiopathic  | Not applicable | Intermediate uveitis | Vitritis | Epiretinal membraneCystoid macular oedema | Missing | RE 0.6, LE 0.7 | RE 1, LE 1 | Intolerance to other immunosuppression | Bilateral | 3 | None |

## **Suppl. Table 2**

## **Comparison of Immunomodulatory treatment, oral corticosteroids and topical treatments prior to commencement of TNFi (baseline visit) and during TNFi therapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Medication** | Prior to TNFi | % | Concomitant with TNFi  | % |
| Prednisolone >10mg PO/day  | 22 | 51.1 | 6 | 14 |
| Prednisolone 1-10mg PO/day | 18 | 41.8 | 23 | 53.5 |
| Prednisolone 0mg |  |  | 15 |  |
| 1 immunomodulatory medications\* | 15 | 37.2 | 25 | 58.1 |
| 2 immunomodulatory medications \* | 25 | 58.1 | 11 | 25.6 |
| Topical Steroid | 17 | 38.6 | 7 | 16.3 |
| Topical Antihypertensive Medication | 9 | 20.5 | 11 | 25.6 |

## **Suppl. Table 2: Comparison of Immunomodulatory treatment, oral corticosteroids and topical treatments prior to commencement of TNFi (baseline visit) and during TNFi therapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Medication | Prior to TNFi | % | Concomitant with TNFi  | % |
| Prednisolone >10mg PO/day  | 22 | 51 | 6 | 14 |
| Prednisolone 1-10mg PO/day | 18 | 42 | 23 | 53.5 |
| Prednisolone 0mg | 4 | 9 | 15 | 39 |
| 1 immunomodulatory medications\* | 15 | 37 | 25 | 58.1 |
| 2 immunomodulatory medications \* | 25 | 58 | 11 | 25.6 |
| Topical Steroid | 17 | 39 | 7 | 16.3 |
| Topical Antihypertensive Medication | 9 | 21 | 11 | 25.6 |

**Suppl. Table 3 Baseline and census visual acuities in patients who lost vision.**

|  |  |  |
| --- | --- | --- |
| Patient | Baseline VA | Visual Acuity at Census |
| 5 | 0.0 | 1.00 |
| 8 | 0.2 | 2.00 |
| 13 | 0.8 | 1.60 |
| 15 | 0.8 | 1.26 |
| 18 | -0.1 | 0.30 |
| 27 | 0.1 | 0.10 |
| 29 | 2.5 | 3.00 |
| 34 | 0.3 | 0.70 |
| 36 | 0.3 | 0.6 |